Ishani Malhotra, CEO and creator of Carcinotech, has a Certificate of Achievement from Harvard Medical School and nine years of experience in stem cell and oncology research. She holds degrees from the University of Edinburgh. Before starting Carcinotech, she gained experience in the fields of oncology and stem cell research while working at Censo Biotechnologies, HCG Oncology hospitals, The Institute of Cytology and Preventive Oncology, and Stempeutics. She has won various accolades on national and international platforms and was featured as a Director of the Year Regional finalist at the Institute of Directors Scotland 2021 awards.
She was most recently named one of Scottish Business Insider’s 35 Rising Stars under 35. She received the Female Entrepreneur of the Year Award and the AccelerateHer 2022 Awards for Science and MedTech the Scottish SME Business Awards 2022’s Award of the Year. To further Carcinotech’s goal of offering individualized medication testing platforms to patients with cancer, she has formed substantial international relationships. She collaborated with businesses and academic institutions, including as Cancer Research UK and Cellink, to enhance the technology’s validation.
Ishani Malhotra launched Carcinotech in 2018 as a result of her study at the University of Edinburgh. To begin the firm’ entrepreneurial journey, Ishani won many business competitions and received grant financing from Scottish Enterprise. Grant-funded proof of concept and validation data allowed her to secure the initial capital needed to market this technology.
An specialist in creating 3D-printed living tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells is Carcinotech, a MedTech business. The cutting-edge models developed by Carcinotech offer a platform for quick, ethical, and precise drug screening as well as pre-clinical and individualized medicine testing.
In order to improve each cancer patient’s likelihood of receiving treatment and surviving, Carcinotech’s aim is to be at the forefront of cancer drug testing and offer individualized medicine testing.
At Carcinotech, we use technology to lessen and eventually do away with the need for animal testing when developing new drugs. We create humanized models to address one of the largest problems the pharmaceutical industry is now facing: the use of animal testing.
Carcinotech seeks to democratize cancer therapy by accelerating the release of superior medications. Ishani aimed to address the cancer industry’s major challenges, including replicating the patients’ tumor microenvironments and immune systems. Carcinotech’s immuno-oncology-focused printed tumors developed from the patient’s immune cells are our solution to this challenge. Traditional organoid models can take up to 90 days to be assay-ready, are less reproducible, and are incompatible with high-throughput systems. Carcinotech’s 3D-printed tumors solve this problem with rapid, consistent tumors in high-throughput formats.
